Advanced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Bobby Graham

Internal Medicine
St. Dominic-Jackson Memorial Hospital
969 Lakeland Dr, 
Jackson, MS 
Advanced in Non-Small Cell Lung Cancer (NSCLC)
St. Dominic-Jackson Memorial Hospital
969 Lakeland Dr, 
Jackson, MS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bobby Graham is an Internal Medicine provider in Jackson, Mississippi. Dr. Graham is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Gastrostomy.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Internal Medicine
Licenses
Internal Medicine in MS
Hospital Affiliations
St Dominic-Jackson Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

St. Dominic-Jackson Memorial Hospital
969 Lakeland Dr, Jackson, MS 39216
Other Locations
Jackson Oncology Associates PLLC
2969 Curran Dr N Ste 200, Jackson, MS 39216

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
View 4 Less Clinical Trials
Similar Doctors
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Samuel Pierce
Internal Medicine
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Samuel Pierce
Internal Medicine

Vicksburg Hma Physician Management LLC

2080 S Frontage Rd Ste 100, 
Vicksburg, MS 
 (41.1 miles away)
601-262-1211
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Samuel Pierce is a primary care provider, practicing in Internal Medicine in Vicksburg, Mississippi. Dr. Pierce is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Gastrostomy, and Endoscopy.

John Studdard
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. John Studdard
Internal Medicine
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. John Studdard
Internal Medicine

Jackson Pulmonary Associates PA

971 Lakeland Dr Ste 1052, 
Jackson, MS 
 (0.3 miles away)
601-981-9503
Languages Spoken:
English
See accepted insurances

John Studdard is an Internal Medicine provider in Jackson, Mississippi. Dr. Studdard is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Nodules, Lung Metastases, Chronic Cough, Pneumonia, and Gastrostomy.

Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Huiling Liu
Internal Medicine
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Huiling Liu
Internal Medicine

St. Dominic-Jackson Memorial Hospital

969 Lakeland Dr, 
Jackson, MS 
 (0.1 miles away)
601-200-4644
Languages Spoken:
English
See accepted insurances

Huiling Liu is a primary care provider, practicing in Internal Medicine in Jackson, Mississippi. Dr. Liu is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Pleurisy, Sepsis, Hospital-Acquired Pneumonia, Gastrostomy, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Graham's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 31 Advanced Conditions
    View All 95 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile